|
|
Development of a UHPLC-MS/MS method suitable for the determination of cabozantinib in blood serum
Kleinová, Jana ; Kozlík, Petr (advisor) ; Hraníček, Jakub (referee)
The aim of this Bachelor thesis was to develop a UHPLC-MS/MS method for the determination of Cabozantinib in blood serum. This method was used to monitor the release of the active substance in a model organism - the rat. First, the mass spectrometer setup was optimized, where MRM transitions for Cabozantinib and isotope-labelled Cabozantinib-D4 were found. For Cabozantinib, an MRM transition of 502.2 → 323.1 was found with optimal energy levels of Q1 = -26.0 V, CE = -40.0 V and Q2 = -22.0 V. For Cabozantinib-D4, the MRM transition of 506.2 → 327.0 was found with optimal energy levels being Q1 = -26.0 V, CE = -39.0 V and Q2 = -22 V. The method setup parameters were as follows: The chromatography column used was a Poroshell 120 EC-C18, 2.1x50 mm, 1.9 um, (Agilent Technologies). The mobile phase consisted of acetonitrile (B) and formic acid (A), the flow rate of the mobile phase was 0.350 ml/min, the analysis time was 5.5 min and the injection volume was 1 μl at gradient elution (time: 0; 0.5; 2.0; 3.0; 3.5; 4.0; 5.5 min, B: 10; 10; 60; 100; 10; 10 %). The method was linear (weighted regression 1/x2 ) with a regression coefficient equal to 0.9978, showing an excellent linearity of the method. The precision (relative standard deviation) of the method was within 14 %. The accuracy (relative error) was...
|
|
|
Effect of the anticancer drug cabozantinib on cytochrome P450 activity
Slobodníková, Eva ; Dračínská, Helena (advisor) ; Václavíková, Radka (referee)
Cabozantinib is an anti-cancer drug used mainly for the treatment of thyroid and renal cell carcinoma. It is classified as a low molecular weight selective tyrosine kinase inhibitor. Tyrosine kinases play a key role in signal transduction and regulation of many cellular processes such as growth, differentiation, and proliferation. The changes in the tyrosine kinase pathways are associated with the formation and progression of tumors where their growth is uncontrolled. Tyrosine kinase inhibitors act on tyrosine kinase receptors, thereby preventing the spread of cancer cells and slowing down the progression of cancer. Because cabozantinib, like other clinically used drugs, is metabolized by cytochromes P450, adverse drug interactions may occur that result in altered pharmacokinetics of the administered drugs and a consequent decrease in the efficacy of these drugs. In this diploma thesis, the effect of cabozantinib on the activity of the main enzymes of phase I biotransformation of xenobiotics, cytochromes P450, was investigated in vitro. The effect on the activity of both rat and human cytochrome P450 isoforms involved in xenobiotic metabolism was studied. CYP isoforms were predominantly incubated with cabozantinib at two concentrations; 10 µM and a concentration corresponding to the substrate...
|
|
|
Effect of rat enzymes on the metabolism of tyrosine kinase inhibitors in vitro and in vivo
Škriabová, Simona ; Indra, Radek (advisor) ; Ptáčková, Renata (referee)
Tyrosine kinase inhibitors are small molecules, orally available, well-tolerated and globally approved drugs for the treatment of several types of tumors. These drugs include vandetanib, cabozantinib, and lenvatinib, which are used to treat thyroid cancer. Vandetanib and cabozantinib are drugs approved for the treatment of medullary thyroid cancer, and lenvatinib is approved for the treatment of differentiated thyroid cancer. In the presented diploma thesis, the in vitro and in vivo metabolism of vandetanib, cabozantinib and lenvatinib was studied. Microsomes isolated from the liver of rats premedicated with pregnenolone carbonitrile were used to study in vitro metabolism. Plasma and urine samples of rats premedicated with individual tyrosine kinase inhibitors were used to study in vivo metabolism. The resulting metabolites were analyzed by high-performance liquid chromatography and subsequently identified using the mass spectrometry method. In the study of in vitro metabolism, when NADPH and cofactors (glucuronic acid and glutathione) were added to the samples, it was found that the most metabolites appeared for all three drugs during a longer incubation periods, and at the same time, it was found that glucuronic acid and glutathione can influence the structure, properties and functions of the...
|
|
|
Metabolism of cabozantinib by enzymes of first phase of biotransformation
Jurečka, Tomáš ; Indra, Radek (advisor) ; Kubíčková, Božena (referee)
Cabozantinib is an anticancer drug that inhibit tyrosine kinases which allow signal pathways important for growth and development of tumors. It is used for treatment of medullary thyroid cancer, hepatocellular carcinoma and kidney cancer. The major enzymes of the first phase of biotransformation that metabolize cabozantinib are cytochromes P450. In this thesis it was studied metabolism of cabozantinib and cytochromes P450 that participated on this metabolism. Hepatic microsomes of rat, mouse and rabbit were used for studying metabolism of cabozantinib in this thesis. It was also focused on the impact of particular isoforms of cytochromes P450 on metabolism of cabozantinib in rat microsomes. Time dependence of cabozantinib conversion in hepatic rat microsomes was also studied. Enzyme kinetics of metabolism of cabozantinib in hepatic rat microsomes, as well as impact of cytochromes P450 inhibitors on the metabolism were included. Metabolites were analyzed by high performance liquid chromatography (HPLC) and mass spectrometry. Formation of metabolites of cabozantinib increased over time to 30 minutes of incubation and with some others to 40 minutes of incubation. Up to five different metabolites were detected in experiments (M1, desmethyl cabozantinib, M3, monohydroxy cabozantinib and cabozantinib...
|
|
|
Study of effects of tyrosine kinase inhibitors and their metabolites on tumour cell lines
Kolárik, Matúš ; Indra, Radek (advisor) ; Vinklářová, Lucie (referee)
Vandetanib, lenvatinib and cabozantinib are inhibitors of receptor tyrosine kinases approved to treat locally advanced or metastatic thyroid gland, kidney and liver cancers. These multi- kinase inhibitors, inhibit phosphorylation of tyrosine moieties of protein, thus modulate cell signalization in cancer cells. Metabolites of vandetanib, lenvatinib and cabozantinib were detected in vitro as well as in vivo in blood and urine. Cytochromes P450 and flavin monooxygenases were identified as primary enzymes participating in metabolism of these drugs. Literature lacks information regarding pharmacological efficacy of vandetanib, lenvatinib and cabozantinib metabolites. The aim of this diploma thesis was the investigation of pharmacological efficacy of N-oxides of vandetanib, lenvatinib and cabozantinib. The viability measurement under normoxic and hypoxic conditions was employed to determined their efficacy. The expression of enzymes of the first phase of xenobiotics metabolism (CYP 450 1A1, 1B1, 3A4 a CYP 450 oxidoreductase) and receptor tyrosine kinases RET and VEGFR2, as well as mechanism of changes in their expression were investigated using western blotting and flow cytometry. High performance liquid chromatography was utilised to investigate possible metabolism of tyrosine kinase inhibitors and...
|
|
|
The effect of antitumor agents on the expression and activity of cytochrome P450 subfamily 2C
Uher, Tomáš ; Dračínská, Helena (advisor) ; Feglarová, Tereza (referee)
Targeted therapies, acting by blocking essential biochemical pathways required for tumor cell growth and survival, are being used lately in multiple cases of cancer treatment. Cabozantinib, a small molecule inhibitor of receptor tyrosine kinases, is an example of a targeted drug, regulating growth, angiogenesis and metastatic pro- gression of medullary thyroid cancer. Such drugs are also often complemented by cytotoxic agents, e.g. ellipticine; however, therapeutic usage of ellipticine itself is limited due to its poor solutibility and variety of adverse effects. In this bachelor thesis, effects of cabozantinib, ellipticine, or their combina- tion on gene and protein expression of cytochromes P450 2C6 and 2C11 have been studied in vivo. Aforementioned cytochromes have an important role in biotrans- formation of xenobiotics in rat liver. Their protein expression has been assessed by Western blot immunoassay technique, while the gene expression was evaluated by quantitative PCR method. Furthermore, the effects of studied substances and their combination on CYP2C6 and CYP2C11 specific activity have been determined by diclofenac 4'-hydroxylation and testosterone 16α-hydroxylation, respectively. Additionally, direct inhibitory effect of cabozantinib on recombinant CYP2C11 rat isoform has been studied in...
|
|
|
Effect of tyrosine kinase inhibitor cabozantinib and cytotoxic alkaloid ellipticine on expression and activity of cytochromes P450 1A1, 1A2 and 1B1
Měkotová, Barbora ; Dračínská, Helena (advisor) ; Jeřábek, Petr (referee)
In recent years, tyrosine kinase inhibitors have been more and more used for the targeted cancer therapy, due to their ability to disrupt intracellular signalling pathways associated with the development of tumours. Cabozantinib is the tyrosine kinase inhibitor which has been approved for the treatment of thyroid cancer and it is also effective against several other types of cancer. However, multiple drugs combination is often used in anticancer therapy, which may result in their cytochrome P450-mediated interactions. Although this may affect the therapeutic effect of the drugs and cause adverse effects on the organism, very little is known about the effect of cabozantinib on biotransformation enzymes. Therefore, the effect of cabozantinib not only alone but also in combination with the known cytostatic ellipticine on the expression and the activity of cytochromes P450 1A1, 1A2 and 1B1 in rat liver and kidney in vivo was studied in this work. The gene expression was determined by quantitative PCR, the amount of protein was studied by Western blotting and consecutive immunodetection. The enzyme activity was studied using specific marker reactions, 7-ethoxyresorufin O-deethylation for CYP1A1, 7-methoxyresorufin O-demethylation for CYP1A2 and 17β-estradiol 4-hydroxylation for CYP1B1. Our results...
|
|
|
Metabolism of tyrosine kinase inhibitor cabozantinib by rat liver microsomes
Jurečka, Tomáš ; Indra, Radek (advisor) ; Mrízová, Iveta (referee)
Cabozantinib is an anticancer drug that was approved for treatment of progressive thyroid cancer by FDA and EMA organizations. Cabozantinib is a tyrosine kinase inhibitor. It blocks signal pathway receptors that are important for growth of tumors. This bachelor's thesis describes the findings about the metabolism of cabozantinib. It studies metabolism of cabozantinib in hepatic microsomes isolated from various laboratory animals (rat, mouse and rabbit) and impact of particular isoforms of cytochromes P450 (CYP) on metabolism of cabozantinib in rat hepatic microsomes. The bachelor's thesis also describes the optimization of method for separation metabolites of cabozantinib by high performance liquid chromatography (HPLC) and also identification of metabolites using mass spectrometry. Up to three different metabolites were detected by utilizing hepatic microsomes isolated from various laboratory animals. Those were M1, monohydroxycabozantinib and O-desmethylcabozantinib. Mouse microsomes oxidized cabozantinib mainly to O-desmethylcabozantinib and rabbit microsomes metabolised cabozantinib mainly to monohydroxycabozantinib. Microsomes from controlled rats produced two metabolites with the overall majority of monohydroxycabozantinib. The highest number of metabolites was produced by microsomes from...
|
|
|
Preparation of anticancer drugs bound in apoferritin
Fürbacherová, Pavlína ; Indra, Radek (advisor) ; Koblihová, Jitka (referee)
Cancer is one of the most serious problems, which modern medicine faces. In recent years, nanotechnologies and their use in medicine, has developed greatly. The aim is to make drug administration more effective and help to improve treatment of cancer illnesses. Incorporation of chemical substance into a nanoparticle can solve the problem with low stability of the drug, and/or it help to eliminate side effects. Nanoparticle apoferritin, which was studied in this thesis, is a form of commonly occurring protein ferritin. Its structure contains cavity, that can be used for incorporation of drug. Its chemical structure (high temperature stability and stability at wide pH range, easy manipulation by changing pH) and its biocompatibility makes apoferritin a potentionally suitable transporter. Presented thesis studied apoferritin's ability to incorporate anticancer drug cabozantinib into its structure. Cabozantinib is tyrosine kinase inhibitor which is used for treatment of thyroid cancer, renal cell carcinoma and hepatocellular carcinoma. The effect of final pH to the formation of the complex of apoferritin with cabozantinib, and stability of this complex was also studied in this thesis. Considering the results we can say that apoferritin is able to encapsulate cabozantinib into its inner structure. As we...
|
guest ::
